ArrayExpress Uploader0humanestrogen receptor alpha mutation: positive; PIK3CA mutation: negativeestrogen receptor alpha mutation: positive; PIK3CA mutation: negativeestrogen receptor alpha mutation: positive; PIK3CA mutation: negativeestrogen receptor alpha mutation: positive; PIK3CA mutation: negativeestrogen receptor alpha mutation: positive; PIK3CA mutation: positiveestrogen receptor alpha mutation: positive; PIK3CA mutation: positiveestrogen receptor alpha mutation: positive; PIK3CA mutation: positiveestrogen receptor alpha mutation: positive; PIK3CA mutation: positiveestrogen receptor alpha mutation: positive; PIK3CA mutation: negativeestrogen receptor alpha mutation: positive; PIK3CA mutation: positiveestrogen receptor alpha mutation: positive; PIK3CA mutation: positiveestrogen receptor alpha mutation: positive; PIK3CA mutation: negativeestrogen receptor alpha mutation: positive; PIK3CA mutation: negativeestrogen receptor alpha mutation: positive; PIK3CA mutation: negativeestrogen receptor alpha mutation: positive; PIK3CA mutation: negativeestrogen receptor alpha mutation: positive; PIK3CA mutation: positiveestrogen receptor alpha mutation: positive; PIK3CA mutation: negativeestrogen receptor alpha mutation: positive; PIK3CA mutation: negativeestrogen receptor alpha mutation: positive; PIK3CA mutation: negativeestrogen receptor alpha mutation: positive; PIK3CA mutation: negativeestrogen receptor alpha mutation: positive; PIK3CA mutation: negativeestrogen receptor alpha mutation: positive; PIK3CA mutation: negativeestrogen receptor alpha mutation: positive; PIK3CA mutation: negativeestrogen receptor alpha mutation: positive; PIK3CA mutation: negativeestrogen receptor alpha mutation: positive; PIK3CA mutation: positiveestrogen receptor alpha mutation: positive; PIK3CA mutation: negativeestrogen receptor alpha mutation: positive; PIK3CA mutation: positiveestrogen receptor alpha mutation: positive; PIK3CA mutation: negativeestrogen receptor alpha mutation: positive; PIK3CA mutation: negativeestrogen receptor alpha mutation: positive; PIK3CA mutation: negativeestrogen receptor alpha mutation: positive; PIK3CA mutation: negativeestrogen receptor alpha mutation: positive; PIK3CA mutation: positiveestrogen receptor alpha mutation: positive; PIK3CA mutation: positiveestrogen receptor alpha mutation: positive; PIK3CA mutation: negativeestrogen receptor alpha mutation: positive; PIK3CA mutation: negativeestrogen receptor alpha mutation: positive; PIK3CA mutation: negativeestrogen receptor alpha mutation: positive; PIK3CA mutation: negativeestrogen receptor alpha mutation: positive; PIK3CA mutation: negativeestrogen receptor alpha mutation: positive; PIK3CA mutation: positiveestrogen receptor alpha mutation: positive; PIK3CA mutation: positiveestrogen receptor alpha mutation: positive; PIK3CA mutation: negativeestrogen receptor alpha mutation: positive; PIK3CA mutation: positiveestrogen receptor alpha mutation: positive; PIK3CA mutation: negative3670arrayexpress_sid4PI3K/AKT pathway plays one of pivotal roles in breast cancer development and maintenance. PIK3CA, coding PIK3 catalytic subunit, is the...21209903E-GEOD-22035/profile/8773/arrayexpressuploader143breastbreast cancercancerDec.12, 2014Falsetranscription-profiling-by-array-of-human-estrog-2E-GEOD-22035_A-AFFY-44Transcription profiling by array of human estrogen receptor alpha positive breast tumors with and without PIK3CA mutations.Sep.15, 2014PI3K/AKT pathway plays one of pivotal roles in breast cancer development and maintenance. PIK3CA, coding PIK3 catalytic subunit, is the oncogene which shows the high frequency of gain-of-function mutations leading to the PI3K/AKT pathway activation in breast cancer. In particular in the ERα-positive breast tumors PIK3CA mutations have been observed in 30% to 40%. However, genes expressed in connection to the pathway activation in breast tumorigenesis remain largely unknown. To identify downstream relevant target genes (and signaling pathways) turned on by the aberrant PI3K/AKT signal in breast tumors, we analyzed gene expression by pangenomic oligonucleotide microarray in a series of 43 ERα-positive tumors with and without PIK3CA mutations. 43 ERα-positive breast tumors including 14 tumors with PIK3CA mutations and 29 tumors without PIK3CA mutattions were used as screening set for microarray.http://www.ebi.ac.uk/arrayexpress/experiments/E-GEOD-22035http://www.ebi.ac.uk/arrayexpress/experiments/E-GEOD-22035/samples/